

Solid-state NMR of membrane-active peptides

EURACT-NMR workshop,
Karlsruhe, 27.1.2010

Anne S. Ulrich
Karlsruhe Institute of Technology




Overview

- 1) Biological membranes and peptides as „magic bullets“
- 2) Structure analysis by ssNMR of lipids (^{31}P) and peptides (^{19}F , ^2H)
- 3) Antimicrobial peptide PGLa: structure, alignment, mobility
- 4) Comparison with other peptides and interactions with „real“ cells




Aim: explain molecular mechanism


here: an antimicrobial peptide attacks a bacterial membrane



Cell penetrating peptides





Cell penetrating mechanism ?









Solid state NMR of lipids

isotopes for studying lipids



- morphology
- dynamics
- structure
- influence of peptides/proteins



Amphiphilic peptides

antimicrobial peptides:
PGLa, Magainin, MSI-103

cell penetrating peptides:
MAP, Transportan

fusogenic peptides:
HIV-FP23, B18

conformation ?
alignment ?
mobility ?
self-assembly ?
aggregation ?

Anisotropy in oriented samples

non-oriented sample:
powder spectrum

oriented sample:
narrow NMR signal

$$\nu \sim (3 \cos^2 \theta - 1)/2$$

Oriented NMR sample

10 mm

- stack of up to 20 glass plates
- each carrying ~ 4000 membranes
- aligned parallel to the magnetic field

Orientational constraints

powder sample B_0 **oriented sample** N

chemical shift anisotropy: $\nu = \Delta_{CSA} (3 \cos^2 \theta - 1)/2$

dipole (quadrupole) splitting: $\Delta \nu_D = \frac{(3 \gamma^2 \hbar)}{2 \pi r^3} \frac{(3 \cos^2 \theta - 1)}{2}$

Solid state NMR of peptides

Place single isotope labels (2H , ^{15}N , ^{19}F) into the peptide frame

orientational constraint θ tilt τ azimuthal rotation ρ

wobble S_{mol} fast rotation

Several labels (θ) reveal peptide conformation (α -helix, β -strand), its alignment (τ , ρ) and dynamics (S_{mol} , rotation in the membrane)






Detect fast peptide diffusion







B_0 sample type static peptide axially averaged

0° 90°


Δ_{max} $S \cdot \Delta_{max}$

same frequency







¹⁹F-NMR at higher concentration




²H-NMR at higher concentration




Binding and re-alignment




Concentration dependence







¹⁹F-NMR temperature dependence



PGLa in lipid gel phase





Choreographic success !




Comparison with other peptides

PGLa (antibiotic from frog skin)
GMASKAGAIAGKIAKVALKAL-NH₂


Magainin (synergistic antibiotic)
GIGKFLHSAKFKGKAFVGEIMNS-COO⁻

MSI-103 (designer-made antibiotic)
KIAGKIAKIAGKIAKIAGKIA-NH₂

MAP (cell-penetrating peptide)
KLALKLALKALKAAKLA-NH₂



Different thresholds



Binding to DMPC: PGLa > MAP > MSI
to DMPG: MSI > MAP > PGLa


Tilting: MSI > D-MAP > PGLa

Immobilization: MAP > MSI = PGLa

Antibiotic activity: MSI > D-MAP > PGLa


Hemolytic activity: MAP > MSI = PGLa

Unexpected behavior of MAP




→ aggregation of MAP at low concentration (1:400)


MAP: KLALKLALKALKAAKLA-NH₂



Steric effect of D-amino acid




both L- and D-CF₃-Phg can be accommodated in α -helix



L-form is compatible with β -sheet but D-form prevents aggregation

Aggregation tendency of MAP



analyzed from D-CF₃-Phg

monomeric only at low concentration


all-L aggregates as β -amyloid

→ aggregation behaviour of MAP can be controlled

Functional state ?




Cell-penetration of MAP epimers



→ effect of aggregation cannot be examined, as MAP is toxic

Any other use of MAP epimers ?



Summary of NMR strategy

1. Check **lipid alignment** by ^{31}P -NMR, detect any perturbation
2. Screen conditions with **sensitive ^{19}F -NMR** ($P/L=1:3000$ to $1:8$)
3. Rough **peptide alignment** (τ , ρ , S_{mol}) from CF_3 -Phg labels
4. Confirm **accurate peptide structure** from D_3 -Ala labels
5. Observe peptide *in vivo* by **background-free ^{19}F -NMR**
6. Do **functional studies** with analogues (e.g. with D-CF_3 -Phg)
7. Derive rules to design new analogues with **improved activity**

Acknowledgements

Erik Strandberg, Parvesh Wadhvani, Sergii Afonin,
 Jochen Bürck, Marina Berditsch, Stephan Grage,
 Ulrich Sternberg, Christian Mink, Ralf Glaser,
 Pierre Tremouilhac, Deniz Tiltak, Marco Ieronimo.

Igor Komarov	University of Kiev
Jesus Salgado, Santi Esteban	University of Valencia
Irene Wacker-Schröder	KIT, IBG-1
Sevil Weinkauff, Sybille Bayerl	TU München

€€ KIT, CFN, DFG, FCI, AvH, DAAD €€

